Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on June 14, 2019, 10:43:41 am
-
Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is highly effective as a salvage treatment for those who have not been cured of hepatitis C virus (HCV) by previous therapy.
The Food and Drug Administration (FDA) has approved 12 weeks of Vosevi as salvage therapy for those who were not previously cured by direct-acting antiviral (DAA) treatment, in particular those who have any genotype of hep C who previously took a DAA from the NS5A inhibitor class and those who have genotype 1a or 3 of HCV and who previously took Sovaldi (sofosbuvir), which is included in Harvoni (ledipasvir/sofosbuvir) and Epclusa (sofosbuvir/velpatasvir).
For more...
https://www.hepmag.com/article/vosevi-works-hepatitis-c-salvage-treatment